Clinical trials: Non-infectious Uveitis
Autoimmune Uveitis, Behçet Disease
Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
This study aimed to discover the composition on the microbiome in several sites of the human body; and to find out the difference in microbiome composition on ocular fluid, blood, and feces before and after therapy in uveitis…
- Conditions
- Autoimmune Uveitis, Behçet Disease, Vogt-Koyanagi-Harada Disease, Idiopathic Uveitis
- Trial name
- NCT04126850
- Where
- Indonesia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fakultas Kedokteran Universitas Indonesia
Non-infectious Anterior Uveitis
SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
A Phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of ADX-102 ophthalmic solution in Subjects with non-infectious anterior-uveitis.
- Trial name
- NCT03131154
- Testing
- ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
- Where
- 27 sites in United States
- Volunteers
- 123 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Non-infectious Intermediate Posterior- or Pan-uveitis
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life.
- Trial name
- NCT05414201
- Testing
- Adalimumab
- Where
- 7 sites in China
- Volunteers
- 87 people
- Sponsor
- AbbVie
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Uveitis
Daclizumab and Sirolimus to Treat Uveitis
This study will examine whether the combination of the drugs daclizumab and sirolimus can effectively treat adults with uveitis, an eye inflammation.
- Trial name
- NCT00078689
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Uveitis
Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
This study will examine the safety and effectiveness of treating uveitis, an eye inflammation, with a monoclonal antibody called daclizumab.
- Trial name
- NCT00070759
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Eye Institute (NEI)
Non-infectious Intermediate and Posterior Uveitis
Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate
BACKGROUND: Uveitis comprises of a group of diseases associated with inflammation of the eye that can lead to vision loss. Some people with uveitis also have macular edema (swelling of the retina at the back of the eye).
- Trial name
- MEXX (NCT01314417)
- Testing
- Methotrexate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Eye Institute (NEI)
Non-Infectious Uveitis of the Posterior Segment of the Eye
A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program
The objective of this extension study is to evaluate the long-term safety of treatment with DE-109 (440 μg) in subjects with non-infectious uveitis of the posterior segment of the eye who have participated in the SAKURA…
- Trial name
- SPRING (NCT02251938)
- Testing
- DE-109 440 μg
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Uveitis, Posterior, Uveitis, Anterior
Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed…
- Conditions
- Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT06085079
- Testing
- Ixekizumab Prefilled Syringe
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye Research and Surgery Institution
Uveitis, Posterior
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uveitis (intraocular inflammation) that has responded to previous steroid therapy.
- Trial name
- NCT05322070
- Testing
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Alimera Sciences
Uveitis
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.
- Trial name
- EYEGUARD™-E (NCT02258854)
- Testing
- Dose 2 gevokizumab
- Where
- 33 sites in United States
- Volunteers
- 69 people
- Sponsor
- XOMA (US) LLC
Non-infectious Uveitis
A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis
In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase) and has shown…
- Trial name
- NCT03634475
- Testing
- PP-001
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 12 people
- Sponsor
- Panoptes Pharma GmbH
Active Non-anterior, Non-infectious Uveitis
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Trial name
- NCT07552012
- Testing
- FXS5626 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Uveitis, Chronic Disease
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
Uveitis and its complications are thought to account for 10 to 15% of preventable blindness in Western countries. The diagnosis of chronic non-infectious uveitis (CNUI) can be made after exclusion of pseudo uveitis or infectious…
- Trial name
- SMOOTH (NCT06390436)
- Testing
- Blood sample, Adalimumab Injection
- Where
- 11 sites in France
- Volunteers
- 320 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Uveitis
Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
- Trial name
- NCT05180526
- Testing
- QLETLI
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
Uveitis
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.
- Trial name
- VISUAL III (NCT01148225)
- Testing
- adalimumab
- Volunteers
- 424 people
- Sponsor
- AbbVie
Non-infectious Uveitis
Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS
prospective, cohort, longitudinal, multicenter, non-randomized study of patients with non-infectious posterior segment uveitis or panuveitis, with a group of control patients (scheduled for cataract or vitreoretinal surgery) and…
- Trial name
- CHRONOS (NCT05928754)
- Testing
- care strategy
- Volunteers
- 2,000 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Non-infectious Uveitis
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant
This is a multi-center, randomized, double-masked, controlled study to evaluate the safety and efficacy of fluocinolone acetonide intravitreal implants for the management of subjects with non-infectious uveitis affecting the…
- Trial name
- NCT00456482
- Testing
- Fluocinolone Acetonide 0.59mg, Fluocinolone Acetonide 2.1mg
- Volunteers
- 239 people
- Sponsor
- Bausch & Lomb Incorporated
Uveitis
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
The purpose of the extension study was to provide patients completing the 28-week core study (NCT01095250) with an opportunity to receive an additional 22 weeks of continuous treatment.
- Trial name
- INSURE (NCT01103024)
- Testing
- AIN457
- Where
- 11 sites in United States, Canada and 3 more
- Sponsor
- Novartis
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Trial name
- NEPTUNE (NCT05523765)
- Testing
- Brepocitinib
- Where
- 15 sites in United States
- Volunteers
- 26 people
- Sponsor
- Priovant Therapeutics, Inc.